Huibin Wang

Huibin Wang

Auto-generated profile, based on publicly available information

Huibin Wang

Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2024 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
HWHuibin Wang
Huibin Wang
IAIkuro Abe
Ikuro Abe
This review highlights the recent advancements in the enzymatic modifications of steroid scaffolds, emphasizing enzymatic hydroxylation, ketoreduction, dehydrogenation, enzymatic cascade reactions, and other modifications.

21 July 2021 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
YYYe Yang
Ye Yang
BHBaichun Hu
Baichun Hu
YYYi Yang
Yi Yang
KGKaihua Gong
Kaihua Gong
HWHuibin Wang
Huibin Wang
JWJian Wang
Jian Wang
The rational design of selective histone deacetylase 2 (HDAC2) inhibitors is beneficial for the therapeutic treatment of liver cancer, though HDAC2 is highly homologous to HDAC8, which may lead to undesired side effects due to the pan-inhibition towards HDAC2 and HDAC8. To clarify the structural basis of selective inhibition towards HDAC2 over HDAC8, we utilized multiple in silico strategies, including sequence alignment, structural comparison, molecular docking, molecular dynamics simulations, free energy calculations, alanine scanning mutagenesis, pharmacophore modeling, protein contacts atlas analysis and QM/MM calculations to study the binding patterns of HDAC2/8 selective inhibitors. Through the whole process described above, it is found that although HDAC2 has conserved GLY154 and PHE210 that also exist within HDAC8, namely GLY151 and PHE208, the two isoforms exhibit diverse binding modes towards their inhibitors. Typically, HDAC2 inhibitors interact with the Zn2+ ions through the core chelate group, while HDAC8 inhibitors adopt a bent conformation within the HDAC8 pocket that inclines to be in contact with the Zn2+ ions through the terminal hydroxamic acid group. In summary, our data comprehensively elucidate the selectivity mechanism towards HDAC2 over HDAC8, which would guide the rational design of selective HDAC2 inhibitors for liver cancer treatment.

12 June 2023 in Nature Catalysis
Verified
Journal Article
Open access
PDF file
TMTakahiro Mori
Takahiro Mori
SKStanislav Kadlcik
Stanislav Kadlcik
SLShuang Lyu
Shuang Lyu
ZKZdenek Kamenik
Zdenek Kamenik
KSKosuke Sakurada
Kosuke Sakurada
IAIkuro Abe
Ikuro Abe
In the biosynthesis of the lincosamide antibiotic celesticetin, the condensation enzyme CcbD generates the lincosamide pharmacophore by forming an amide bond between the carrier protein (CP)-tethered proline and ergothioneine-conjugated thiooctose. Although the function of CcbD has been investigated, its substrate specificity, structures and catalytic mechanisms remain unclear. Here we show the structure–function analyses of CcbD. Our biochemical analysis revealed that CcbD exhibits promiscuous substrate specificity towards CP-tethered acyl substrates to generate unnatural lincosamides. Furthermore, structural analyses indicated that CcbD possesses an unusual overall fold, while the N-terminal region shows weak similarity to cysteine proteases. Thus, CcbD, like cysteine proteases, utilizes the Cys-His-Glu catalytic triad to form amide bonds in a CP-dependent manner, which is significantly different from other known amide bond-forming enzymes. Furthermore, the structures of the CcbD/thiooctose complex and the cross-linked CcbD/CcbZ-CP complex, as well as structure-based mutagenesis, revealed the intimate structural details of the CP-dependent amide bond formation reaction.

14 February 2022 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
JGJiyang Guo
Jiyang Guo
XGXiao Gao
Xiao Gao
DQDong Qian
Dong Qian
HWHuibin Wang
Huibin Wang
XJXian Jia
Xian Jia
SYSong You
Song You
Ketoreductase (KRED)-catalyzed asymmetric reduction of prochiral ketones is an attractive method to synthesize chiral alcohols. Herein, two KREDs LfSDR1-V186A/E141I and CgKR1-F92I with complementary stereopreference were identified towards reduction of apremilast prochiral ketone intermediate 1a. LfSDR1-V186A/E141I exhibited >99% conversion and 99.2% ee yielding an apremilast chiral alcohol intermediate ((R)-2a) at 50 g L−1 substrate loading. Furthermore, we investigated the substrate scope of β-keto sulfones by using LfSDR1-V186A/E141I and CgKR1-F92I to produce both enantiomers of the corresponding β-hydroxy sulfones, with good-to-excellent conversion (up to >99%) and enantioselectivity (up to 99.9% ee) being obtained in most cases. Finally, the gram-scale synthesis of (R)-2a was performed by employing the crude enzyme of LfSDR1-V186A/E141I and BsGDH to afford the desired enantiomer with >99% conversion, 85.9% isolated yield and 99.2% ee. This study presents a biocatalytic strategy to synthesize chiral β-hydroxy sulfones.

10 November 2020 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
HWHuibin Wang
Huibin Wang
YWYing Wang
Ying Wang
CLChunshi Li
Chunshi Li
HWHanxun Wang
Hanxun Wang
XGXiaohui Geng
Xiaohui Geng
FZFengjiao Zhang
Fengjiao Zhang
PI3K α and β are Class IA PI3K isoforms that share a highly homologous ATP binding site, differing only in a few residues around the binding site.

23 June 2021 in New Journal of Chemistry
Verified
Journal Article
Closed access
PDF file
YXYunting Xin
Yunting Xin
SZShuhao Zhou
Shuhao Zhou
HWHuibin Wang
Huibin Wang
BHBaichun Hu
Baichun Hu
ZZZhigang Zhang
Zhigang Zhang
TSTiemin Sun
Tiemin Sun
Human sodium dependent glucose co-transporters (SGLTs) are attractive targets for diabetes treatment, and the development of SGLT1/SGLT2 dual inhibitors has received substantial attention in recent years due to their better glycemic control and fewer side effects. In this study, multiple computational strategies were employed to reveal the three-dimensional qualitative structure–activity relationship (3D-QSAR) of SGLT1/SGLT2 dual inhibitors. The homology models of SGLT1 and SGLT2 were constructed, which were refined by molecular dynamics (MD) simulation and validated by Ramachandran plots, ERRAT and the ProSA program. Molecular docking was performed to generate the pharmacophoric conformers and investigate the interactions between ligands and SGLT proteins. MD simulations combined with MM-GBSA calculation were used to evaluate the binding stability, and alanine scanning mutagenesis (ASM) was used to explore the role of specific amino acids in protein–ligand interactions at the same time. The molecular field analysis (MFA) was carried out on 35 SGLT1 inhibitors and 46 SGLT2 inhibitors through a genetic partial least-squares (G/PLS) method to generate statistically significant 3D-QSAR models (R2 SGLT1 = 0.999 and R2 SGLT2 = 0.963), with cross validated coefficients (Q2 CV = 0.742 and 0.753). Furthermore, new compounds were designed according to the summarized SAR information, which were predicted to be more potent with satisfactory pharmacokinetic properties and expected binding modes. In brief, our results will greatly support the development of SGLT1/SGLT2 dual inhibitors.